Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07009210

AI Assisted Personalized Legacy Program (Reflections: My Story) for Patients With Serious Illness

The purpose of this study is to determine if it is feasible and acceptable to recruit for and deliver the AI Assisted Personalized Legacy Program intervention to patients with serious illness.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Mayo Clinic, Phoenix, Arizona, United States

Loading trial locations.

About this study

This study is an investigator-initiated, multi-site Mayo Clinic prospective minimal risk pilot study to determine feasibility and acceptability of an AI Assisted Personalized Legacy Program. The AI Assisted Personalized Legacy Program intervention is a brief, individualized psychotherapy that aims to relieve psycho-emotional and existential distress and improve the experiences of patients whose lives are impacted by serious illness. This therapy offers patients an opportunity to reflect on their life with a trained facilitator and share their thoughts and memories with family and other people in their life. The sessions are recorded and transcribed. The interventionist will work with patients to edit the document and provide a final legacy document for patient to keep and give to loved ones.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Participant population: Adults with serious illness - defined as a health condition that carries a high risk of mortality

Inclusion criteria

for patients:

  • Age ≥18 years
  • English fluency
  • Provide informed consent
  • Ability to complete questionnaire(s) by themselves or with assistance

Exclusion criteria

  • Other psychological co-morbidities such as untreated schizophrenia, bipolar disease
  • Recent suicide attempt or psychiatric illness severe enough that hospitalization has been necessary in last 6 months
  • Active delirium
  • Advanced dementia
  • Participation in concurrent legacy offerings through the palliative care clinic

Treatment and study plan

AI Assisted Personalized Legacy Program

Behavioral

AI Assisted Personalized Legacy Program will be facilitated by a clinician trained in legacy work.

Primary outcomes

  1. Feasibility Number

    Time frame: 2 years

    Study feasibility will be measured by the number of participants who enrolled and finished the study.

  2. Acceptability

    Time frame: 5-10 days post-delivery of the final legacy document

    Acceptability, as measured by the 7-item Was it Worth It (WIWI Questionnaire).The questions are answered as either "yes, no, or uncertain," overall perception of quality of life change, overall perception of study experience, one open-ended feedback question, and an option to talk with someone about concerns. Positive responses indicate acceptability. Results are reported as individual items.

Study contacts

Contact information is provided by the study sponsor or research team.

Dept. of Medicine Research Hub

CONTACT

[email protected]

507-266-1944

Melissa Felt

CONTACT

[email protected]

507-255-4162

Sponsors and collaborators

Lead sponsor

Mayo Clinic

Other

Registry information

Official study title

Feasibility and Acceptability of AI Assisted Personalized Legacy Program (Reflections: My Story) for Patients With Serious Illness

Important dates

Study start
2025
Primary completion
2026
Study completion
2027
First posted
Jun 6, 2025
Registry last updated
Jun 17, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.